Skip to main content
Journal cover image

Older patients with myeloma derive similar benefit from autologous transplantation.

Publication ,  Journal Article
Sharma, M; Zhang, M-J; Zhong, X; Abidi, MH; Akpek, G; Bacher, U; Callander, NS; Dispenzieri, A; Freytes, CO; Fung, HC; Gale, RP; Gasparetto, C ...
Published in: Biol Blood Marrow Transplant
November 2014

Autologous hematopoietic cell transplantation (AHCT) for plasma cell myeloma is performed less often in people >70 years old than in people ≤70 years old. We analyzed 11,430 AHCT recipients for plasma cell myeloma prospectively reported to the Center for International Blood and Marrow Transplant Research between 2008 and 2011, representing the majority of US AHCT activity during this period. Survival (OS) was compared in 3 cohorts: ages 18 to 59 years (n = 5818), 60 to 69 years (n = 4666), and >70 years (n = 946). Median OS was not reached for any cohort. In multivariate analysis, increasing age was associated with mortality (P = .0006). Myeloma-specific mortality was similar among cohorts at 12%, indicating an age-related effect on nonmyeloma mortality. Analyses were performed in a representative subgroup comparing relapse rate, progression-free survival (PFS), and nonrelapse mortality (NRM). One-year NRM was 0% for age >70 years and 2% for other ages (P = not significant). The three-year relapse rate was 56% in age 18 to 59 years, 61% in age 60 to 69 years, and 63% age >70 (P = not significant). Three-year PFS was similar at 42% in age 18 to 59 years, 38% in age 60 to 69 years, and 33% in age >70 years (P = not significant). Postrelapse survival was significantly worse for the older cohort (P = .03). Older subjects selected for AHCT derived similar antimyeloma benefit without worse NRM, relapse rate, or PFS.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Biol Blood Marrow Transplant

DOI

EISSN

1523-6536

Publication Date

November 2014

Volume

20

Issue

11

Start / End Page

1796 / 1803

Location

United States

Related Subject Headings

  • Young Adult
  • Treatment Outcome
  • Transplantation, Autologous
  • Prospective Studies
  • Multiple Myeloma
  • Middle Aged
  • Male
  • Immunology
  • Humans
  • Hematopoietic Stem Cell Transplantation
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Sharma, M., Zhang, M.-J., Zhong, X., Abidi, M. H., Akpek, G., Bacher, U., … Hari, P. (2014). Older patients with myeloma derive similar benefit from autologous transplantation. Biol Blood Marrow Transplant, 20(11), 1796–1803. https://doi.org/10.1016/j.bbmt.2014.07.013
Sharma, Manish, Mei-Jie Zhang, Xiaobo Zhong, Muneer H. Abidi, Görgün Akpek, Ulrike Bacher, Natalie S. Callander, et al. “Older patients with myeloma derive similar benefit from autologous transplantation.Biol Blood Marrow Transplant 20, no. 11 (November 2014): 1796–1803. https://doi.org/10.1016/j.bbmt.2014.07.013.
Sharma M, Zhang M-J, Zhong X, Abidi MH, Akpek G, Bacher U, et al. Older patients with myeloma derive similar benefit from autologous transplantation. Biol Blood Marrow Transplant. 2014 Nov;20(11):1796–803.
Sharma, Manish, et al. “Older patients with myeloma derive similar benefit from autologous transplantation.Biol Blood Marrow Transplant, vol. 20, no. 11, Nov. 2014, pp. 1796–803. Pubmed, doi:10.1016/j.bbmt.2014.07.013.
Sharma M, Zhang M-J, Zhong X, Abidi MH, Akpek G, Bacher U, Callander NS, Dispenzieri A, Freytes CO, Fung HC, Gale RP, Gasparetto C, Gibson J, Holmberg LA, Kindwall-Keller TL, Klumpp TR, Krishnan AY, Landau HJ, Lazarus HM, Lonial S, Maiolino A, Marks DI, Mehta P, Mikhael Med JR, Nishihori T, Olsson R, Ramanathan M, Roy V, Savani BN, Schouten HC, Scott E, Tay J, To LB, Vesole DH, Vogl DT, Hari P. Older patients with myeloma derive similar benefit from autologous transplantation. Biol Blood Marrow Transplant. 2014 Nov;20(11):1796–1803.
Journal cover image

Published In

Biol Blood Marrow Transplant

DOI

EISSN

1523-6536

Publication Date

November 2014

Volume

20

Issue

11

Start / End Page

1796 / 1803

Location

United States

Related Subject Headings

  • Young Adult
  • Treatment Outcome
  • Transplantation, Autologous
  • Prospective Studies
  • Multiple Myeloma
  • Middle Aged
  • Male
  • Immunology
  • Humans
  • Hematopoietic Stem Cell Transplantation